7-Hydroxycannabidiol (7-OH-CBD) is an active metabolite of cannabidiol, generated in the body from cannabidiol by the action of the enzyme CYP2C19.[1] While methods have been developed for its synthetic production,[2] and measurement of levels in the body following consumption of cannabidiol,[3] its pharmacology has been relatively little studied, though it has been found to possess similar anticonvulsant effects to cannabidiol itself,[4] as well as lowering blood triglyceride levels. Like its precursor CBD, it is not known to exhibit any psychoactive effects on the body and is known to counter the psychoactive effects of THC if it is present at the same time. This mode of action in 2015 was discovered to be at least contributing in part by being a non competitive negative allosteric modulator of the Cannabinoid receptor type 1.[5]
^Vlad RA, Hancu G, Ciurba A, Antonoaea P, Rédai EM, Todoran N, Silasi O, Muntean DL (October 2020). "Cannabidiol - therapeutic and legal aspects". Die Pharmazie. 75 (10): 463–469. doi:10.1691/ph.2020.0076 (inactive 1 November 2024). PMID33305718.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
^Tchilibon S, Mechoulam R (October 2000). "Synthesis of a primary metabolite of cannabidiol". Organic Letters. 2 (21): 3301–3. doi:10.1021/ol006369a. PMID11029195.
^WO 2015198078, Colin S, Nick Jones N, Whalley B, Stephens G, Williams C, "7-hydroxy-cannabidiol (7-OH-CBD) and/or 7-oh-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy.", published 30 December 2015, assigned to GW Pharma Limited
^WO 2015198077, Stott C, Duncan M, Di Marzo V, Silverstri C, Martella A, "7-Hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)", published 30 December 2015, assigned to GW Pharma Limited
